CD7 and acute myeloid leukemia: AML patients were divided into two groups according to CD7 expression; the median OS time was 24 months in the CD7+ group and 51 months in the CD7- group, and the difference in OS between the two groups was not significantly different (p>0.05, Figure 2C); the median RFS time was 20 months and 19 months in the CD7+ and CD7- groups, respectively, and the difference was also not significantly different (p>0.05, Figure 2D).